KARS1 and tuberculosis: Previously, we havepresented a novel preclinical candidate (49) for thetreatment of TB through targeting LysRS. This manuscript reports thefull medicinal chemistry program thatsuccessfully optimized a fragment-like hit into a potent nanomolarinhibitor, with minimal addition of heavy atoms.